Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, under the ticker symbol WWB, the Shanghai-based firm announced.
The company priced its initial public offering at $17.00 per share. By the close of its first trading session, shares had risen to $28.50, representing a gain of roughly 68 percent from the offering price — a notably strong first-day performance by recent biotech IPO standards.
Read more Inverse Anthropic ETFs Offer Bears a Way to Bet Against ANT →
Windward Bio operates in the immunology space and is classified as clinical-stage, meaning its pipeline candidates are actively being tested in human trials but have not yet reached commercialization. The company's connection to Qiming Venture Partners, a prominent venture capital firm with deep roots in Chinese life sciences investment, underscores the cross-border nature of the listing.
The Nasdaq debut marks a significant milestone for Windward Bio as it seeks access to U.S. capital markets to advance its immunology research programs. A strong opening-day performance can provide a company with added visibility among institutional investors, though biotech valuations remain closely tied to clinical data readouts in subsequent quarters.
Continue reading at All Financial Services & Investing.